EUCTR2015-003132-12-BE进行中（未招募）1 期
apixaban in end -stage renal disease
ZLeuven0 个研究点目标入组 24 人开始时间: 2015年7月23日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 24
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •patients aged 18 to 85 years, treated with maintenance dialysis thrice weekly, written and signed informed consent
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 12
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 12
排除标准
- •treated with oral vitamin K antagonists, recent major surgery, recent severe bleeding episode requiring blood transfusion and / or hospitalization, concurrent moderate to severe liver dysfunction
研究者
相似试验
已完成
4 期
Apixaban in HemodialysisEnd-stage Renal DiseaseNCT02672709Jewish General Hospital7
撤回
不适用
Safety and Efficacy of Apixaban in Severe Renal ImpairmentRenal Disease, End StageAnticoagulant-induced BleedingNCT03399305Albert Einstein College of Medicine
已完成
2 期
Apixaban in End-stage Kidney Disease : A Pharmacokinetics StudyAnticoagulant ToxicityESRDNCT03456648Universitaire Ziekenhuizen KU Leuven24
招募中
不适用
Pharmacokinetics of Apixaban in Peritoneal DialysisAtrial FibrillationNCT05532878Chinese University of Hong Kong50
撤回
不适用
The Effectiveness and Safety of Apixaban in NVAF Patients With History of Osteoporosis and/or Fracture: A Nation-wide Population Based StudyAtrial FibrillationNCT04198844Pfizer